A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB).

Geens, W. (Speaker), Schwarze, J. K. (Contributor), Bertels, C. (Contributor), Tijtgat, J. (Contributor), Awada, G. (Contributor), F Vaeyens (Contributor), Louise Cras (Contributor), Vanbinst, A. (Contributor), Everaert, H. (Contributor), Michotte, A. (Contributor), Toon Janssen (Contributor), Ben Caljon (Contributor), Thomas Cauwenbergh (Contributor), Bruneau, M. (Contributor), Forsyth, R. (Contributor), Tuyaerts, S. (Contributor), Neyns, B. (Contributor), Duerinck, J. (Contributor)

Activiteit: Talk or presentation at a conference

Periode26 mrt 2022
EvenementstitelBSN annual meeting
Mate van erkenningNational